EFFICACY AND SAFETY OF MIBEFRADIL IN HYPERTENSION VERSUS LOSARTAN

目前这项研究的目的是评估 米贝拉地尔和氯沙坦对舒张期平均舒张压变化的影响 在积极治疗8周后测量血压(SDBP)。 这项研究包括为期4周的安慰剂磨合期和随后的8周 治疗期。在治疗期间的前4周， 患者接受米贝法地尔(50 Mg)或氯沙坦(50 Mg)治疗。在每周 对研究药物有反应的患者，平均为90毫米汞柱，将 继续以相同的剂量继续服用相同的研究药物四周。 平均浓度为90毫米汞柱的患者将滴定到最后一剂。 在接下来的4周内每天服用100毫克，一直持续到第8周。

The objective of the current study is to evaluate the differnce between mibefradil and losartan in the change of mean trough sitting diastolic blood pressure (SDBP) measurements after 8 weeks of active treatment. This study includes a 4-week placebo run-in period followed by an 8-week treatment period. During the first 4 weeks of the treatment period, the patients receive either mibefadil (50mg), or losartan(50mg). At week 4, patients responding to the study drug, mean trough SDBP<90mmHg, will continue on the same study drug at the same dose for four more weeks. Patients with mean trough SDBP>90mm Hg, will titrate up to a final dose of 100 mg once daily for the remaining 4 weeks through weeek 8.